The rate of false positives in clinical trials should be set higher for certain hard-to-treat cancers, suggest researchers.
Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.
Researchers need to design more translationally relevant animal studies to improve the potential for success in human clinical trials, according a recent report.
Poor communication between healthcare providers and clinical research professionals is contributing to low recruitment rates, according to a recent study by Tufts.
An increasing number of clinical trials and a decreasing amount of unemployment are creating a significant talent demand as the contract research industry continues to experience employee turnover.
With or without a preferred provider – what do pharma sponsors look for in a contract research organization?
Pharmaceutical companies are more likely than their suppliers to cite cost improvement over time as the most effective metric for measuring supplier performance, according to a recent report.
The Global Biological Standards Institute (GBSI) has outlined an action plan after finding the frequency of irreproducible preclinical research exceeds 50% – costing the US nearly $28bn.
At least 50,000 volunteers are needed to participate in clinical trials for Alzheimer’s disease – the global cost of which is expected to reach $2 trillion by 2030.
Clinical trials supporting changes to high-risk medical devices often lack quality data, according to a recent report.
A "new set of leaders" emerged in the contract manufacturing organization (CMO) industry over the past year, though many remain unheard of, according to a recent report.
Clinical trial consent forms should be more concise moving forward, say NIH researchers in a recent report.
Researchers have developed and tested a method to determine how relevant mouse models are to human disease to better enable comparison of pharmacological targets across species.
Lack of trust has become less of a barrier to clinical trial participation, though more work needs to be done as information access and service levels receive low marks in a recent survey.
The CRO market in Asia has “massive implications” as it continues to emerge as a preferred destination for clinical trials – a global market expected to reach $57bn by 2020.
The industry is expected to use an increasing amount of real world evidence, including social media data, which will be used to support new drug applications, according to a recent Tufts report.
Clinical trial participants often misunderstand the differences between research and clinical care – a ‘longstanding problem’ that an enhanced informed consent process could diminish, says report.
Clinical study database challenges are delaying clinical trial timelines as CROs and sponsors must manage an increasing variety of trial data, according to a recent study.